MODERN PROBLEMS OF WORKING OUT OF NEW MEDICAL PRODUCTS
In article problems which developers of new medical products face are formulated and shown. They can be broken into three directions conditionally: economic efficiency - technology - a science. The successful decision all three directions of problems will allow to promote considerably in working out of new highly effective medicines.
R.A. Islamov, A.A. Azembayev
RSE "Scientific Center for Anti-infectious Drugs", Almaty
1. Drug discovery handbook. Ed. by Sh.C. Gad. New Jersey: John Wiley&Sons, 2005. 1471p
2. LaMattina J.L. The impact of mergers on pharma-ceutical R&D // Nature Reviews Drug Discovery. 2010. Vol. 10. P.559-560
3. Paul S.M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge // Nature Rev. Drug Discov. 2010. Vol. 9. P.203–214
4. Goodyear M. Learning from the TGN1412 trial // BMJ. 2006. Vol. 332. P. 677-678
5. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs // Journal of Health Economics. 2003. Vol. 22. P.151–185
6. Early drug development. Ed. By M.N. Cayen New Jersey: John Wiley & Sons, 2010. 630p
7. DiMasi J.A., Grabowski H.G. The cost of biophar-maceutical r&d: is biotech different? // Manage. Decis. Econ. 2007. Vol. 28. P.469–479
8. Hopkins A.L. Network pharmacology: the next para-digm in drug discovery // Nat. Chem. Biol. 2008. Vol.4. No.11. P.682-690
9. Chang R.L., Xie L., Xie L., Bourne Ph.E., Palsson B.O. Drug off-target effects predicted using structural analysis in the context to metabolic network model // PLoS Computational Biology. 2010. Vol. 6. No. 9. e1000938
10. Marshall G.R. Limiting assumptions in structure-based design: binding entropy // J. Comput. Aided. Mol. Des. 2012. Vol. 26. P.3-8
11. Chang Ch. A., Chen W., Gilson M.K. Ligand config-urational entropy and protein binding // PNAS. 2007. Vol. 104. No. 5. P.1534-1539
12. Shuman C.F., Hämäläinen M.D., Danielson U.H. Kinetic and thermodynamic characterization of HIV-1 prote-ase inhibitors // J. of Molecular Recognition. 2004. Vol. 17. No. 2. P.106-119
13. Сарвилина И.В., Каркищенко В.Н., Горшкова Ю.В. Междисциплинарные исследования в медицине. М.: Техносфера, 2007. 368с.
14. Rauch P.J., Chudnovskiy A., Robbins C.S. et al. In-nate response activator b cells protect against microbial sepsis // Science, 2012. DOI:10.1126/science.1215173
15. Kumarasamy K.K., Toleman M.A., Walsh T.R. et al Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study // The Lancet Infectious Diseases. 2010. Vol. 10. No. 9. P. 597-602
16. Principles of laboratory animal science. Eds. L.F. Van Zutphen, V. Baumans, A.C. Beynen. Elsevier, 2001. 416p.
17. Scheer N., Kapelyukh Y., McEwan J., Beuger V., Stanley L.A., Rode A., Wolf C.R. Modeling human cyto-chrome p450 2d6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines // Mol. Pharmacol. 2012. Vol. 81. No. 1. P.63-72
Number of Views: 252
Category of articles:
Health organization the Republic of Kazakhstan
Bibliography link
Р.А. Исламов, А.А. Азембаев СОВРЕМЕННЫЕ ПРОБЛЕМЫ РАЗРАБОТКИ НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ //Наука и Здравоохранение 2012.№ 1. С. 5-6 R.A. Islamov A.A. Azembayev MODERN PROBLEMS OF WORKING OUT OF NEW MEDICAL PRODUCTS // Nauka i Zdravookhranenie. 2012.№ 1. С. 5-6 Р.А. Исламов, А.А. Азембаев ҚАЗІРГІ ЗАМАНҒЫ ЖАҢА ДӘРІЛІК ЗАТТАРДЫ ӨҢДЕУДЕГІ МӘСЕЛЕЛЕРДІ ШЕШУ // Ғылым және Денсаулық сақтау 2012.№ 1. С. 5-6Related publications:
REALIZATION OF SCREENING PROGRAMMS IN KAZAKHSTAN AT THE PRESENT STAGE
ACTUAL ASPECTS OF PRIMARY MEDICAL SANITARY CARE
EFFICIENCY SCREENING EXAMINATIONS THE EAST KAZAKHSTAN POPULATION WITHIN THE FRAMEWORK OF REFORMING OF PUBLIC HEALTH SYSTEM OF THE REPUBLIC OF KAZAKHSTAN ON PROGRAM «SALAMATTY KAZAKHSTAN»
MODERN PROBLEMS OF WORKING OUT OF NEW MEDICAL PRODUCTS
ABOUT THE INTEGRATION OF SCIENCE AND PRACTICE